Sponsor
This activity is jointly sponsored by Medical Learning Institute, Inc., a nonprofit medical accreditation company, and Center of Excellence Media, LLC.

Target Audience
This activity was developed for pharmacists and other healthcare professionals practicing in a managed care environment.

Learning Objectives
Upon completion of this activity, the participant will be able to:

• Provide payers with a practical understanding of the key clinical, business, and regulatory factors, guidelines, and research advances involving NHL treatment that providers are using as the basis for their treatment decisions
• Offer payers a multi-stakeholder commentary on this information, to identify the impact of these changes to treatment on different stakeholders
• Illuminate the different perspectives and incentives of the various stakeholders involved in NHL treatment decisions: patients, providers, payers, purchasers, distributors, regulatory agencies, and manufacturers
• Align incentives with providers and transform payer drug management policies into patient-centered, value-based models

Commercial Support Acknowledgment
This activity is supported by an educational grant from Cephalon.

Instructions for Credit
There is no fee for this activity. After reading this CE activity in its entirety, participants must complete the posttest and evaluation. The posttest and evaluation can be completed online at www.mlicme.org/p10033.html. Upon completion of the evaluation and scoring 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc., at 609-333-1693 or cgusack@mlicme.org.

Pharmacists Designation

Medical Learning Institute, Inc., is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-10-014-H01-P.

Faculty Disclosures
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.

Dwight D. Kloth, PharmD, FCCP, BCOP, is on the Advisory Board of Amgen, Eisai, and Ortho-Biotech, and on the Speaker’s Bureau of Amgen. He discusses bendamustine plus rituximab combination.

Gary C. Yee, PharmD, FCCP, BCAP, is on the Advisory Board of Amgen and Eisai. He discusses bendamustine, bortezomib, ofatumumab, and temsirolimus.

Caroline Helwick has no financial relationships to disclose.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Estimated time to complete activity: 1 hour
Initial Release Date: April 15, 2010
Expiration Date: April 15, 2011

PDF: 

Download PDF